| Title |
MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
|
|---|---|
| Published in |
Pharmacogenomics and Personalized Medicine, March 2017
|
| DOI | 10.2147/pgpm.s107047 |
| Pubmed ID | |
| Authors |
Maitane Umerez, Ángela Gutierrez-Camino, Carmen Muñoz-Maldonado, Idoia Martin-Guerrero, Africa Garcia-Orad |
| Abstract |
Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, C677T and A1298C, affecting MTHFR activity, have been widely studied as potential markers of MTX toxicity and/or outcome in pediatric ALL. In this review, we show that the majority of published reports do not find association or present opposite effect. Therefore, MTHFR C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or outcome in pediatric ALL. The efforts should be focused on other genes, such as transporter genes or microRNA-related genes. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 54 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 19% |
| Student > Master | 7 | 13% |
| Researcher | 6 | 11% |
| Student > Bachelor | 4 | 7% |
| Student > Doctoral Student | 3 | 6% |
| Other | 6 | 11% |
| Unknown | 18 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 10 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 17% |
| Medicine and Dentistry | 7 | 13% |
| Agricultural and Biological Sciences | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 23 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2017.
All research outputs
#20,247,404
of 25,748,735 outputs
Outputs from Pharmacogenomics and Personalized Medicine
#1
of 1 outputs
Outputs of similar age
#239,425
of 325,441 outputs
Outputs of similar age from Pharmacogenomics and Personalized Medicine
#1
of 1 outputs
Altmetric has tracked 25,748,735 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1 research outputs from this source. They receive a mean Attention Score of 0.8. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,441 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them